Analysis of bladder cancer therapeutic drug clinical trials in mainland China and globally.
1/5 보강
[BACKGROUND AND OBJECTIVE] Bladder cancer presents a significant challenge in clinical practice.
APA
Kuang J, An Y, et al. (2026). Analysis of bladder cancer therapeutic drug clinical trials in mainland China and globally.. Biochimica et biophysica acta. Reviews on cancer, 1881(2), 189558. https://doi.org/10.1016/j.bbcan.2026.189558
MLA
Kuang J, et al.. "Analysis of bladder cancer therapeutic drug clinical trials in mainland China and globally.." Biochimica et biophysica acta. Reviews on cancer, vol. 1881, no. 2, 2026, pp. 189558.
PMID
41679353
Abstract
[BACKGROUND AND OBJECTIVE] Bladder cancer presents a significant challenge in clinical practice. This review aims to investigate trends in BC drug trials globally and in China from 2010 to 2025, with particular emphasis on the period form 2010 to 2019, as 2018 marked the advent of the immunotherapy era.
[METHODS] Data were extracted from clinical trial registries, regulatory databases (including the CDE platform), and scientific publications. Eligibility criteria included clinical trials evaluating systemic therapies for BC. Quality assessment was performed using the Cochrane Risk of Bias Tool and MINORS criteria.
[KEY FINDINGS AND LIMITATIONS] Between 2010 and 2019, 448 BC trials were identified globally, with a compound annual growth rate of 17.8%. The United States, China, and Japan were the leading countries in terms of the number of trials. China contributed 13 registered BC drugs, involving 33 trials, that primarily focused on chemical agents in Phase II studies. Globally, 131 BC agents were studied, including 63 biopharmaceuticals (48% of which were antibody-based, predominantly PD-1/PD-L1 inhibitors) and 68 chemotherapies. From 2020 to 2025, overall trends remained; similar, with chemotherapy continuing to dominate and the United States, China, Japan, and European countries remaining the primary contributors. However, limitations such as potential reporting bias and varying methodological quality should be taken into account.
[CONCLUSION AND CLINICAL IMPLICATIONS] Chemotherapy remains a cornerstone in BC treatment, while biopharmaceutical agents are emerging as promising alternatives. The rapid expansion of immune checkpoint inhibitors and novel modalities, such as antibody-drug conjugates, represents a shift in therapeutic strategies. China's increasing involvement in clinical trials and advancements in biopharmaceutical research capacity suggest substantialsignificant potential for future contributions to this evolving landscape. Clinicians should consider incorporating biological agents into treatment algorithms while remaining vigilant about resistance mechanisms.
[METHODS] Data were extracted from clinical trial registries, regulatory databases (including the CDE platform), and scientific publications. Eligibility criteria included clinical trials evaluating systemic therapies for BC. Quality assessment was performed using the Cochrane Risk of Bias Tool and MINORS criteria.
[KEY FINDINGS AND LIMITATIONS] Between 2010 and 2019, 448 BC trials were identified globally, with a compound annual growth rate of 17.8%. The United States, China, and Japan were the leading countries in terms of the number of trials. China contributed 13 registered BC drugs, involving 33 trials, that primarily focused on chemical agents in Phase II studies. Globally, 131 BC agents were studied, including 63 biopharmaceuticals (48% of which were antibody-based, predominantly PD-1/PD-L1 inhibitors) and 68 chemotherapies. From 2020 to 2025, overall trends remained; similar, with chemotherapy continuing to dominate and the United States, China, Japan, and European countries remaining the primary contributors. However, limitations such as potential reporting bias and varying methodological quality should be taken into account.
[CONCLUSION AND CLINICAL IMPLICATIONS] Chemotherapy remains a cornerstone in BC treatment, while biopharmaceutical agents are emerging as promising alternatives. The rapid expansion of immune checkpoint inhibitors and novel modalities, such as antibody-drug conjugates, represents a shift in therapeutic strategies. China's increasing involvement in clinical trials and advancements in biopharmaceutical research capacity suggest substantialsignificant potential for future contributions to this evolving landscape. Clinicians should consider incorporating biological agents into treatment algorithms while remaining vigilant about resistance mechanisms.